A5017578322- Gastrointestinal Tumor Research and Treatment
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Lung Cancer Treatments and Mutations
- Metastasis and carcinoma case studies
- PI3K/AKT/mTOR signaling in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Surgical Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Anorectal Disease Treatments and Outcomes
- Immune Cell Function and Interaction
- Soft tissue tumor case studies
- Enhanced Recovery After Surgery
- Oral and Maxillofacial Pathology
- Galician and Iberian cultural studies
- Gastrointestinal disorders and treatments
- Neuroblastoma Research and Treatments
- Liver Disease Diagnosis and Treatment
- Lung Cancer Research Studies
Yokohama City University Medical Center
2019-2024
Yokohama City University
2019-2024
National Cancer Center Hospital East
2020-2022
Japan Community Healthcare Organization
2017
Hokkaido hospital
2017
Hokkaido University
1996-2016
Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of shows primary resistance or short-term disease control. Since malignant effusions represent an immune-suppressed niche, we investigated whether peritoneal involvement without ascites is poor prognostic factor dMMR/MSI-H metastatic colorectal cancer (mCRC) and gastric (mGC)...
This study performed a comprehensive molecular characterization of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) gastrointestinal (GI) tumors to elucidate predictors response PD-1 blockade.Forty-five patients with MSI-H/dMMR GI tumors, including gastric cancer, colorectal cholangiocarcinoma, small intestine pancreatic and duodenal receiving blockade were analyzed. We conducted the genomic profiling by whole-exome sequencing or targeted next-generation sequencing....
Abstract Purpose: Transcriptomic profiling was performed for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) gastrointestinal tumors to determine the predictors of response PD-1 blockade. Experimental Design: Thirty-six patients with MSI-H/dMMR tumors, including gastric cancer, colorectal cholangiocarcinoma, small intestine and pancreatic being treated blockade were analyzed. We conducted transcriptomic analysis using RNA sequencing data, consensus molecular subtypes...
Abstract Background KRAS is one of the most frequently mutated oncogenes in colorectal cancer (CRC). Recently, a novel therapy targeting G12C mutation has demonstrated promising activities for corresponding advanced solid tumors, including metastatic CRC (mCRC). However, prognostic impact remains unclear patients with mCRC. Materials and Methods We retrospectively reviewed medical records mCRC who received first-line chemotherapy between January 2005 December 2017 at four large oncology...
Spontaneous regression (SR) of many malignant tumors has been well documented, with an approximate incidence one per 60,000–100,000 cancer patients. However, SR colorectal (CRC) is very rare, accounting for less than 2% such cases. We report a case transverse colon in 80-year-old man undergoing outpatient follow-up after surgical treatment early gastric cancer. Colonoscopy (CS) revealed Borrmann type II tumor the measuring 30 × mm. Because patient underwent anticoagulant therapy, we did not...
Abstract Background Surgical site infection ( SSI ) is a common morbidity in patients undergoing colorectal surgery, and the focus of previous studies has primarily been on incisional . Most reports thus far have focused open surgery rather than laparoscopic (Lap CR ). Therefore, aim present study was to identify risk factors for elective Lap Methods This retrospective conducted evaluate occurrence From January 2008 June 2018, 1825 consecutive with preoperative diagnosis cancer who underwent...
Abstract Aim Although rectal neuroendocrine tumors (NETs) are considered to be rare low‐grade malignancies when lymph node metastasis (LNM) is present, their degree of malignancy comparable that colorectal cancer (CRC). However, it remains unclear as which patients require radical dissection. The aim this study was elucidate the risk factors for LNM and develop a risk‐scoring system help determine appropriate therapeutic approaches. Methods In study, we examined 103 with NETs who underwent...
The two key concerns in treating locally advanced rectal cancer (LARC) are as follows: (i) prolonging survival by reducing distant metastases and (ii) maintaining anorectal function quality of life surviving patients safely avoiding resection. To resolve these issues, recent years, total neoadjuvant therapy (TNT), a preoperative combination chemoradiotherapy or short-course radiotherapy (SCRT) systemic chemotherapy, has been developed multidisciplinary treatment LARC. There have no...
The C-TASK-FORCE phase I/II and Danish randomized II trials reported the promising efficacy of trifluridine/tipiracil (TAS102) plus bevacizumab (BEV) in patients with chemorefractory metastatic colorectal cancer (mCRC). However, there had been no direct comparative III trial to compare between TAS102 BEV standard therapy either or regorafenib monotherapy.We retrospectively reviewed medical records mCRC who received BEV, monotherapy, monotherapy after chemotherapies during 2013-2019.Patients...
TPS276 Background: Non-operative management (NOM) may enable more patients (pts) with a complete clinical response (cCR) or near-complete (nCR) after total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC) to avoid subsequent radical surgery, possibly maintaining the anorectal function and quality of life (QoL). The PRODIGE-23 trial demonstrated that triplet regimen before chemoradiotherapy (CRT) significantly improved outcomes in comparison CRT. However, there have been no...
Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects crossover administration REG TFTD on patient remain unclear. present study evaluated association between exposure to overall (OS) mCRC using data from REGOTAS study. Patients Methods: We analyzed registered study, which retrospectively compared efficacy safety use or as...
症例は72歳女性.61歳時に胃癌に対して開腹胃全摘術,結腸前経路Roux-en-Y再建法を施行していた.今回は下部消化管内視鏡検査で横行結腸癌と診断され,腹腔鏡下拡大結腸右半切除術を施行した.腫瘍の局在は挙上空腸よりも口側の横行結腸で,肛門側断端距離を10cm以上確保するためには挙上空腸間膜と横行結腸間膜の癒着を剥離し,脾彎曲までの剥離授動が必要であった.挙上空腸間膜の損傷による挙上空腸の血流障害時には再吻合が必要となるため,肛門側断端距離は十分確保できないが,挙上空腸のすぐ背側の横行結腸,腫瘍から肛門側約5cmの位置で腸管を切離し,体腔内吻合とする方針とした.再建は自動縫合器を用いて回腸と横行結腸を端々吻合するデルタ吻合を施行した.術後経過良好で術後11日目に退院となった.胃全摘術後の横行結腸癌の症例では授動範囲が最小限ですむ体腔内吻合が治療の選択肢の1つになると考えられた.
71 Background: Total neoadjuvant therapy (TNT) has dramatically shifted the treatment paradigm for locally advanced rectal cancer (LARC), prolonging survival with high rates of pathologic complete response (pCR) and introducing opportunities nonoperative management (NOM). However, there is a need robust predictive biomarkers TNT efficacy, local regrowth in NOM, overall prognosis. Circulating tumor DNA (ctDNA) minimally invasive biomarker used to detect molecular residual disease (MRD)...
症例は43歳，男性．胸痛を主訴に近医受診．CTで肝左葉に腫瘤を認め，血清学的検査で肝エキノコックス症の診断となり当科紹介．術前画像診断で肝左葉～尾状葉に13cm大の病巣を認め，肝部下大静脈（inferior vena cava;IVC）は病巣により完全閉塞し，右副腎にも浸潤．側副血行路として奇静脈系が発達．肝左3区域・尾状葉切除および肝部IVC，右副腎合併切除を施行．肝上部IVCは右肝静脈を温存し，一部病巣を残して切除．肝下部IVCは腎静脈合流部頭側で縫合閉鎖．IVCは非再建とした．術後経過は良好でalbendazole （ABZ）を内服し，補助療法中である．周辺臓器に浸潤した肝エキノコックス症では可及的な病巣切除と術後ABZ内服で長期予後が期待できるため，積極的な手術を行う必要がある．IVC完全閉塞例に対する肝切除では，術前に側副血行路の発達があればIVC合併切除後の再建は不要と考える．
症例は34歳の女性で，嘔気と腹痛を主訴に近医を受診した．CTで肝右葉を主座とする長径20 cmの腫瘤を認め，肝血管腫の診断で当科を紹介受診した．手術待機期間中に腹痛が増悪し，緊急入院となった．術前精査で肝前区域～内側区に23×15 cmの肝血管腫を認め，右肝静脈と中肝静脈は圧排され，肝右3区域にうっ血に伴う側副血行路を認めた．左肝静脈と門脈臍部は開存していた．肝右3区域切除でCT volumetryによる有効肝切除率は80%と算出されたが，Tc-99m-labeled galactosyl human serum albumin single photon emission CT/CT（99mTc-GSA SPECT/CT）fusion imageで算出した機能的肝切除率は39.2%であり，十分な残肝能を予測できたため，肝右3区域切除術を施行した．術後経過は良好で，術後14日目に退院した．
Numerous novel biologics are emerging for refractory ulcerative colitis (UC), but rising medical costs a serious problem. Sulfasalazine (SASP) is an inexpensive drug. Although the effectiveness of 5-aminosalicylic acid (5-ASA) and SASP UC equivalent, sometimes appears effective in daily clinical practice. has dose-dependent side effects there considerable amount cases high-dose intolerance SASP. To solve this problem, we have provided 'half therapy' patients with UC, where 5-ASA administered...